PT1318992E - Derivados do imidazole como inibidores da cinase raf - Google Patents
Derivados do imidazole como inibidores da cinase rafInfo
- Publication number
- PT1318992E PT1318992E PT01967528T PT01967528T PT1318992E PT 1318992 E PT1318992 E PT 1318992E PT 01967528 T PT01967528 T PT 01967528T PT 01967528 T PT01967528 T PT 01967528T PT 1318992 E PT1318992 E PT 1318992E
- Authority
- PT
- Portugal
- Prior art keywords
- imidazole
- rain
- derivatives
- inhibitors
- cinase
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000006726 chronic neurodegeneration Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 102000009929 raf Kinases Human genes 0.000 abstract 1
- 108010077182 raf Kinases Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0023193A GB0023193D0 (en) | 2000-09-21 | 2000-09-21 | Compounds |
| GB0023208A GB0023208D0 (en) | 2000-09-21 | 2000-09-21 | Compounds |
| GB0023196A GB0023196D0 (en) | 2000-09-21 | 2000-09-21 | Compouds |
| GB0023197A GB0023197D0 (en) | 2000-09-21 | 2000-09-21 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1318992E true PT1318992E (pt) | 2005-11-30 |
Family
ID=27447885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT01967528T PT1318992E (pt) | 2000-09-21 | 2001-09-19 | Derivados do imidazole como inibidores da cinase raf |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7199137B2 (pt) |
| EP (1) | EP1318992B1 (pt) |
| JP (1) | JP2004509882A (pt) |
| KR (1) | KR20030030027A (pt) |
| CN (1) | CN1471523A (pt) |
| AT (1) | ATE300529T1 (pt) |
| AU (1) | AU2001287901A1 (pt) |
| BR (1) | BR0114023A (pt) |
| CA (1) | CA2423154A1 (pt) |
| CY (1) | CY1105251T1 (pt) |
| CZ (1) | CZ2003793A3 (pt) |
| DE (1) | DE60112312T2 (pt) |
| DK (1) | DK1318992T3 (pt) |
| ES (1) | ES2242767T3 (pt) |
| HU (1) | HUP0301181A2 (pt) |
| IL (1) | IL154949A0 (pt) |
| MX (1) | MXPA03002449A (pt) |
| NO (1) | NO20031270L (pt) |
| PL (1) | PL361397A1 (pt) |
| PT (1) | PT1318992E (pt) |
| WO (1) | WO2002024680A1 (pt) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2228629T3 (es) | 1999-11-22 | 2005-04-16 | Smithkline Beecham Plc | Derivados de imidazol y su uso como inhibidores de raf-quinasa. |
| AU2001235838A1 (en) * | 2000-03-06 | 2001-09-17 | Smithkline Beecham Plc | Imidazol derivatives as raf kinase inhibitors |
| ES2289004T3 (es) | 2000-11-20 | 2008-02-01 | Smithkline Beecham Corporation | Nuevos compuestos. |
| GB0112348D0 (en) * | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| US20040192689A1 (en) * | 2001-09-05 | 2004-09-30 | Dean David Kenneth | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| WO2003022832A1 (en) * | 2001-09-05 | 2003-03-20 | Smithkline Beecham P.L.C. | Pyridylfurans and pyrroles as raf kinase inhibitors |
| GB0121488D0 (en) * | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| GB0121490D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Ciompounds |
| AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| WO2003086467A1 (en) * | 2002-04-08 | 2003-10-23 | Smithkline Beecham Corporation | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor |
| US20040132726A1 (en) * | 2002-08-09 | 2004-07-08 | Astrazeneca Ab And Nps Pharmaceuticals, Inc. | New compounds |
| RU2352568C9 (ru) | 2002-08-09 | 2009-06-27 | Астразенека Аб | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 |
| MXPA05001590A (es) | 2002-08-09 | 2005-05-23 | Astrazeneca Ab | Compuestos que tienen actividad en los receptores metabotropicos de glutamato. |
| AU2003257329C1 (en) | 2002-08-19 | 2010-07-22 | Lorus Therapeutics Inc. | 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents |
| UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| US20090264494A1 (en) * | 2002-10-18 | 2009-10-22 | Board Of Regents, The University Of Texas System | Use of neuroprotective 3-substituted indolone compositions |
| US20050250837A1 (en) * | 2002-10-18 | 2005-11-10 | D Mello Santosh R | Use of C-Raf inhibitors for the treatment of neurodegenerative diseases |
| CA2522333A1 (en) * | 2003-04-14 | 2004-10-21 | Novartis Ag | Methods for treating proliferative diseases and for monitoring the effectiveness of treatment of proliferative diseases |
| AU2004275888B2 (en) * | 2003-10-02 | 2008-09-18 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| CA2545942C (en) * | 2003-11-14 | 2012-07-10 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| WO2006126177A2 (en) | 2005-05-25 | 2006-11-30 | Genesense Technologies Inc. | 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer |
| CA2622295C (en) | 2005-09-12 | 2019-01-15 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
| US9957569B2 (en) * | 2005-09-12 | 2018-05-01 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
| US20090018142A9 (en) * | 2006-05-02 | 2009-01-15 | Zhengping Zhuang | Use of phosphatases to treat tumors overexpressing N-CoR |
| WO2008058239A2 (en) * | 2006-11-08 | 2008-05-15 | The Regents Of The University Of Michigan | Spink1 as a prostate cancer marker and uses thereof |
| WO2008097561A1 (en) | 2007-02-06 | 2008-08-14 | Lixte Biotechology Holdings, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
| CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| ATE533861T1 (de) | 2007-07-06 | 2011-12-15 | Univ Michigan | Mipol1-etv1-gen-neuanordnungen |
| BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
| JP5270553B2 (ja) | 2007-08-23 | 2013-08-21 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2009028629A1 (ja) | 2007-08-29 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
| CN101854804B (zh) | 2007-10-01 | 2014-07-23 | 利克斯特生物技术公司 | Hdac抑制剂 |
| WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
| US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
| WO2010064611A1 (ja) | 2008-12-01 | 2010-06-10 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| WO2011034906A2 (en) * | 2009-09-17 | 2011-03-24 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
| US20130040983A1 (en) * | 2010-01-08 | 2013-02-14 | Jean-Michel Vernier | Raf kinase inhibitors |
| US8945556B2 (en) | 2010-11-19 | 2015-02-03 | The Regents Of The University Of Michigan | RAF gene fusions |
| MX2013009931A (es) | 2011-04-18 | 2013-10-01 | Eisai R&D Man Co Ltd | Agentes terapeuticos contra tumores. |
| WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
| WO2013022766A1 (en) * | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
| CN103159735B (zh) * | 2011-12-10 | 2015-12-09 | 通化济达医药有限公司 | 取代的咪唑激酶抑制剂 |
| CN103159736B (zh) * | 2011-12-10 | 2015-05-13 | 通化济达医药有限公司 | 取代的吡唑激酶抑制剂 |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| US20150232452A1 (en) * | 2012-09-19 | 2015-08-20 | Ruga Corporation | Novel raf kinase inhibitors |
| CA2903866A1 (en) | 2013-03-20 | 2014-09-25 | Aptose Biosciences Inc. | 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer |
| EA201591931A1 (ru) | 2013-04-09 | 2016-05-31 | Ликсте Байотекнолоджи, Инк. | Композиции оксабициклогептанов и оксабициклогептенов |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
| ES2775579T3 (es) | 2013-10-04 | 2020-07-27 | Aptose Biosciences Inc | Composiciones para el tratamiento del cáncer |
| IL290857B2 (en) | 2016-12-08 | 2023-03-01 | Lixte Biotechnology Inc | Oxabicycloheptanes for immune response modulation |
| AU2018360477A1 (en) | 2017-10-30 | 2020-06-04 | Aptose Biosciences Inc. | Aryl imidazoles for the treatment of cancer |
| CN108484587A (zh) * | 2018-06-03 | 2018-09-04 | 刘思良 | 一种Raf激酶抑制剂及其在癌症治疗中的应用 |
| WO2022249192A1 (en) * | 2021-05-27 | 2022-12-01 | Ramot At Tel-Aviv University Ltd. | Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236917A (en) * | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| WO1995003297A1 (en) | 1993-07-21 | 1995-02-02 | Smithkline Beecham Corporation | Imidazoles for treating cytokine mediated disease |
| US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
| US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| WO1996041645A1 (en) | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations |
| US5717100A (en) * | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
| AU727939B2 (en) | 1996-04-03 | 2001-01-04 | Merck & Co., Inc. | A method of treating cancer |
| ATE294174T1 (de) * | 1996-06-10 | 2005-05-15 | Merck & Co Inc | Substituierte imidazole mit cytokinin- inhibirender wirkung |
| WO1997048672A2 (en) | 1996-06-21 | 1997-12-24 | Allergan Sales, Inc. | Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| SK284788B6 (sk) | 1996-10-15 | 2005-11-03 | G. D. Searle & Co. | Použitie inhibítorov cyklooxygenázy-2 pri liečení a prevencii neoplázie |
| CZ146999A3 (cs) | 1996-10-30 | 1999-09-15 | Schering Corporation | Piperazinové deriváty jako antagonisté neurokininu |
| WO1999021555A2 (en) | 1997-10-27 | 1999-05-06 | Takeda Chemical Industries, Ltd. | Adenosine a3 receptor antagonists |
| WO1999025717A1 (en) | 1997-11-14 | 1999-05-27 | Sankyo Company, Limited | Pyridylpyrrole derivatives |
| ATE355856T1 (de) | 1998-07-30 | 2007-03-15 | Point Biomedical Corp | Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln |
-
2001
- 2001-09-19 EP EP01967528A patent/EP1318992B1/en not_active Expired - Lifetime
- 2001-09-19 PL PL01361397A patent/PL361397A1/xx not_active Application Discontinuation
- 2001-09-19 KR KR10-2003-7004109A patent/KR20030030027A/ko not_active Withdrawn
- 2001-09-19 IL IL15494901A patent/IL154949A0/xx unknown
- 2001-09-19 BR BR0114023-0A patent/BR0114023A/pt not_active Application Discontinuation
- 2001-09-19 AT AT01967528T patent/ATE300529T1/de not_active IP Right Cessation
- 2001-09-19 AU AU2001287901A patent/AU2001287901A1/en not_active Abandoned
- 2001-09-19 DK DK01967528T patent/DK1318992T3/da active
- 2001-09-19 WO PCT/GB2001/004195 patent/WO2002024680A1/en not_active Ceased
- 2001-09-19 CN CNA018182135A patent/CN1471523A/zh active Pending
- 2001-09-19 DE DE60112312T patent/DE60112312T2/de not_active Expired - Fee Related
- 2001-09-19 US US10/380,891 patent/US7199137B2/en not_active Expired - Fee Related
- 2001-09-19 MX MXPA03002449A patent/MXPA03002449A/es unknown
- 2001-09-19 CA CA002423154A patent/CA2423154A1/en not_active Abandoned
- 2001-09-19 ES ES01967528T patent/ES2242767T3/es not_active Expired - Lifetime
- 2001-09-19 CZ CZ2003793A patent/CZ2003793A3/cs unknown
- 2001-09-19 JP JP2002529090A patent/JP2004509882A/ja active Pending
- 2001-09-19 HU HU0301181A patent/HUP0301181A2/hu unknown
- 2001-09-19 PT PT01967528T patent/PT1318992E/pt unknown
-
2003
- 2003-03-19 NO NO20031270A patent/NO20031270L/no not_active Application Discontinuation
-
2005
- 2005-09-06 CY CY20051101069T patent/CY1105251T1/el unknown
-
2007
- 2007-01-22 US US11/625,406 patent/US20070135433A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CZ2003793A3 (cs) | 2004-04-14 |
| HUP0301181A2 (en) | 2007-02-28 |
| CN1471523A (zh) | 2004-01-28 |
| AU2001287901A1 (en) | 2002-04-02 |
| JP2004509882A (ja) | 2004-04-02 |
| DK1318992T3 (da) | 2005-11-21 |
| BR0114023A (pt) | 2004-02-03 |
| MXPA03002449A (es) | 2003-06-19 |
| NO20031270D0 (no) | 2003-03-19 |
| DE60112312D1 (de) | 2005-09-01 |
| ES2242767T3 (es) | 2005-11-16 |
| EP1318992B1 (en) | 2005-07-27 |
| ATE300529T1 (de) | 2005-08-15 |
| US7199137B2 (en) | 2007-04-03 |
| EP1318992A1 (en) | 2003-06-18 |
| US20070135433A1 (en) | 2007-06-14 |
| PL361397A1 (en) | 2004-10-04 |
| DE60112312T2 (de) | 2005-12-29 |
| KR20030030027A (ko) | 2003-04-16 |
| CY1105251T1 (el) | 2010-03-03 |
| NO20031270L (no) | 2003-05-19 |
| CA2423154A1 (en) | 2002-03-28 |
| US20040038964A1 (en) | 2004-02-26 |
| WO2002024680A1 (en) | 2002-03-28 |
| IL154949A0 (en) | 2003-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1318992E (pt) | Derivados do imidazole como inibidores da cinase raf | |
| GB0121490D0 (en) | Ciompounds | |
| BR0318383A (pt) | derivados de pirazoloisoquinolina como inibidores de cinase | |
| LTC1620113I2 (lt) | Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui | |
| BRPI0413427A (pt) | derivados de piridilpirrol ativos como inibidores da cinase | |
| AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
| WO2008080001A3 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| DE60318177D1 (de) | Rho-kinase inhibitoren | |
| UA98629C2 (ru) | Соединения и способ модуляции киназ | |
| UA95244C2 (ru) | Соединения и способ модулирования активности киназ, и показания для их применения | |
| MXPA05012573A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa. | |
| NO20032759L (no) | 2-fenylbenzimidazoler og imidazo-[4,5]-pyridiner som Cds1/Chk2-inhibitorerog adjuvanter for kjemoterapi eller strålingsterapi ved behandlingav cancer | |
| NO20054082L (no) | Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander | |
| ATE408412T1 (de) | Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration | |
| IS8125A (is) | Kínasólínafleiður til að meðhöndla krabbamein | |
| UY28130A1 (es) | Compuestos de indazol y composiciones farmaceuticaspara inhibr proteinquinasas, y procedimientos para su uso. | |
| NO20071798L (no) | Dermalt pafore formuleringer for behandling av hudsykdommer i dyr | |
| DK1325011T3 (da) | Fremgangsmåder og forbindelser til behandling af proliferative sygdomme | |
| GB0121494D0 (en) | Compounds | |
| UY29709A1 (es) | "compuestos quimicos" | |
| NO20055307D0 (no) | Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer | |
| ATE325115T1 (de) | Pyrimidinderivate als selektive cox-2-inhibitoren | |
| ES2187446T3 (es) | Composicion para el tratamiento de la psoriasis. | |
| DK1521752T3 (da) | Makrocykliske forbindelser til behandling af cancer |